The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT2C receptors (Q62373349)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Philippe Marin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Maud Kamal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Ralf Jockers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Benjamin Chanrion

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Joël Bockaert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Clotilde Mannoury la Cour

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Mark J Millan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

15 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

The International Journal of Neuropsychopharmacology

15 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

768-783

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

Agomelatine, the first melatonergic antidepressant: discovery, characterization and development

15 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Role of melatonin in the regulation of human circadian rhythms and sleep

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

New approaches to developing antidepressants by enhancing monoaminergic neurotransmission

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Serotonin 5-HT2c agonists mimic the effect of light pulses on circadian rhythms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Endogenous serotonin excites striatal cholinergic interneurons via the activation of 5-HT 2C, 5-HT6, and 5-HT7 serotonin receptors: implications for extrapyramidal side effects of serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Melatonin analogues as agonists and antagonists in the circadian system and other brain areas

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Pharmacology of 5HT(2C) receptor-mediated ERK1/2 phosphorylation: agonist-specific activation pathways and the impact of RNA editing

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Beta-arrestin-biased ligands at seven-transmembrane receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

5-HT2A and 5-HT2C receptors and their atypical regulation properties

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Discontinuation symptoms in depression and anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

New selective ligands of human cloned melatonin MT1 and MT2 receptors.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Successful use of S20098 and melatonin in an animal model of delayed sleep-phase syndrome (DSPS).

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Ligand dependency of 5-hydroxytryptamine 2C receptor internalization

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

A Review of the Pharmacological and Clinical Profile of Mirtazapine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Serotonin 5-ht2 receptors: molecular and genomic diversity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Improving antidepressant drugs: update on recently patented compounds

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Serotonin 5-hydroxytryptamine2C receptor signaling in hypothalamic proopiomelanocortin neurons: role in energy homeostasis in females

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Characterisation of agonist binding on human 5-HT2C receptor isoforms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Effect of agomelatine in the chronic mild stress model of depression in the rat.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Behavioural and neuroplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Comparison of G-protein selectivity of human 5-HT2C and 5-HT1A receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Region-dependent regulation of mesoaccumbens dopamine neurons in vivo by the constitutive activity of central serotonin2C receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Fragments, network biology and designing multiple ligands

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Phospholipase D activation by endogenous 5-hydroxytryptamine 2C receptors is mediated by Galpha13 and pertussis toxin-insensitive Gbetagamma subunits

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

RNA Editing Induces Variation in Desensitization and Trafficking of 5-Hydroxytryptamine 2c Receptor Isoforms

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Physical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

SB 242084, a Selective and Brain Penetrant 5-HT 2C Receptor Antagonist

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Improved donor/acceptor BRET couples for monitoring beta-arrestin recruitment to G protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Altered RNA editing of serotonin 2C receptor in a rat model of depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Serotonin 5-HT2C receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Circadian rhythm disturbances in depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Serotonin 5-HT2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Regulation of serotonin 5-HT2C receptors by chronic ligand exposure.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001045

7 January 2021

10.1017/S1461145710001045

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20946699%20AND%20SRC:MED&resulttype=core&format=json